News Releases

Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Highlights For the three months ended September 30, 2026: Revenues of $691.5 million Book-to-bill ratio of 1.12x, resulting in 1.12x book-to-bill for the trailing 12 months GAAP net

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference: Jefferies Global

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Highlights Collaboration aims to accelerate precision oncology research in Australia Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening

Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026.

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea’s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights Fortrea enters into a definitive agreement to acquire the Early

Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2 million Book-to-bill ratio of 1.06x, resulting in 1.12x book-to-bill for the trailing 12 months GAAP

DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.